Literature DB >> 27035216

MicroRNA-130a promotes the metastasis and epithelial-mesenchymal transition of osteosarcoma by targeting PTEN.

Jiansong Chen1, Dingding Yan2, Weiliang Wu1, Jian Zhu1, Wensong Ye1, Qiang Shu3.   

Abstract

MicroRNAs, which serve as post-transcriptional modulators of numerous genes, have been found to be important regulators during the pathogenesis of osteosarcoma. This study demonstrates for the first time that microRNA-130a (miR-130a) is significantly upregulated in osteosarcoma, and associated with the metastasis of osteosarcoma. Elevated level of miR-130a was closely correlated with poor clinical features and prognosis of osteosarcoma patients. In vitro assays revealed that miR-130a could potentiate the migration, invasion and the epithelial-mesenchymal transtion (EMT) of osteosarcoma cells. Moreover, phosphatase and tensin homolog (PTEN) was confirmed as not only a direct downstream target but also a functional mediator of miR-130a. MiR-130a exerted promoting effects on metastatic behavior and EMT of osteosarcoma cells through suppressing PTEN expression. Based on these findings, we conclude that miR-130a is a promising prognostic biomarker for osteosarcoma patients, and targeting miR-130a may be a potential treatment option for osteosarcoma patients with metastasis.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27035216     DOI: 10.3892/or.2016.4719

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  26 in total

Review 1.  Deconvoluting the complexity of microRNAs in autophagy to improve potential cancer therapy.

Authors:  Dahong Yao; Yingnan Jiang; Suyu Gao; Lei Shang; Yuqian Zhao; Jian Huang; Jinhui Wang; Shilin Yang; Lixia Chen
Journal:  Cell Prolif       Date:  2016-07-20       Impact factor: 6.831

Review 2.  miRNA signatures in childhood sarcomas and their clinical implications.

Authors:  G M Viera; K B Salomao; G R de Sousa; M Baroni; L E A Delsin; J A Pezuk; M S Brassesco
Journal:  Clin Transl Oncol       Date:  2019-04-04       Impact factor: 3.405

Review 3.  Emerging roles of non-coding RNAs in the pathogenesis, diagnosis and prognosis of osteosarcoma.

Authors:  Chongchong Wang; Juehua Jing; Li Cheng
Journal:  Invest New Drugs       Date:  2018-08-06       Impact factor: 3.850

4.  Anti-leukemic activity of microRNA-26a in a chronic lymphocytic leukemia mouse model.

Authors:  L D'Abundo; E Callegari; A Bresin; A Chillemi; B K Elamin; P Guerriero; X Huang; E Saccenti; E M A A Hussein; F Casciano; P Secchiero; G Zauli; G A Calin; G Russo; L J Lee; C M Croce; G Marcucci; S Sabbioni; F Malavasi; M Negrini
Journal:  Oncogene       Date:  2017-08-07       Impact factor: 9.867

5.  MicroRNA-2682-3p inhibits osteosarcoma cell proliferation by targeting CCND2, MMP8 and Myd88.

Authors:  Fan Zhang; Yanjie Zhu; Guoxin Fan; Shuo Hu
Journal:  Oncol Lett       Date:  2018-06-27       Impact factor: 2.967

6.  miR-130a Deregulates PTEN and Stimulates Tumor Growth.

Authors:  Huijun Wei; Ri Cui; Julian Bahr; Nicola Zanesi; Zhenghua Luo; Wei Meng; Guang Liang; Carlo M Croce
Journal:  Cancer Res       Date:  2017-09-21       Impact factor: 12.701

Review 7.  MicroRNAs in Bone Metastasis.

Authors:  Eric Hesse; Hanna Taipaleenmäki
Journal:  Curr Osteoporos Rep       Date:  2019-06       Impact factor: 5.096

8.  Overexpression Pattern of miR-301b in Osteosarcoma and Its Relevance with Osteosarcoma Cellular Behaviors via Modulating SNX10.

Authors:  Yaozong Wang; Naikun Sun; Zheyi Zhang; Yuanyuan Zhou; Hongyi Liu; Xu Zhou; Ying Zhang; Yilin Zhao
Journal:  Biochem Genet       Date:  2022-06-22       Impact factor: 1.890

Review 9.  Heterogeneous Circulating Tumor Cells in Sarcoma: Implication for Clinical Practice.

Authors:  Chiara Agnoletto; Chiara Caruso; Cecilia Garofalo
Journal:  Cancers (Basel)       Date:  2021-05-02       Impact factor: 6.639

Review 10.  Molecular mechanisms underpinning sarcomas and implications for current and future therapy.

Authors:  Victoria Damerell; Michael S Pepper; Sharon Prince
Journal:  Signal Transduct Target Ther       Date:  2021-06-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.